search
Back to results

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

Primary Purpose

Abscess

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
oral trimethoprim/sulfamethoxazole
Placebo
Sponsored by
Baylor College of Medicine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Abscess focused on measuring abscess, Abscesses in the pediatric emergency population

Eligibility Criteria

90 Days - 18 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

1.) Abscess < 5 cm (< 5 cm of induration and fluctuance) requiring incision and drainage 2.) Age > 90 days and < 18 years 3.) Abscess on the trunk, scalp, extremities, or axillae

Exclusion Criteria:

  1. Multiple abscesses
  2. Abscess located on the hands, face, or perineum
  3. Abscess as a result of a bite wound
  4. Immunocompromised patient - i.e., diabetes, sickle cell, chronic steroid therapy (> 10 days), etc.
  5. Previously failed 48 hours or greater therapy on any antibiotic regimen 6.) Drug allergy to TMP/SMX

7.) Fever > or = 102.2 degrees Fahrenheit in the previous 24 hours 8.) Systemic symptoms on presentation - i.e., nausea , vomiting, persistent tachycardia, hypotension, diaphoresis, etc.

9.) Signs /symptoms of another infection or illness - i.e., influenza, croup, etc.

Sites / Locations

  • Texas Children's Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

oral trimethoprim/sulfamethoxazole

placebo

Arm Description

subjects with abscesses less than 5cm will be randomized to either study med or placebo

Placebo after incision and drainage of abscess less than 5 cm.

Outcomes

Primary Outcome Measures

Number of Participants With Abscess Resolution
Outcomes will be measured by resolution of size, tenderness, and induration with erythema by parental report 7 - 10 days after initial visit to the Emergency Center

Secondary Outcome Measures

Number of Participants Requiring Admission for Failure of Abscess Resolution
Percentage of patients requiring admission to Texas Children's or another hospital within 10 days of incision and drainage
Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve
For the antibiotic arm, we determined if the child was prescribed a different antibiotic. For the placebo arm, we determined if the child received a prescription for an antibiotic at a subsequent visit (e.g., in the emergency department, by their pediatrician, etc) within 10 days of incision and drainage

Full Information

First Posted
December 28, 2007
Last Updated
June 22, 2020
Sponsor
Baylor College of Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT00691600
Brief Title
Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage
Official Title
Phase 3 Study Comparing Bactrim to Placebo in the Management of Abscesses < 5cm in the Pediatric Population.
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
December 2007 (undefined)
Primary Completion Date
April 2010 (Actual)
Study Completion Date
April 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Baylor College of Medicine

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to compare rates of cure of abscesses with and without antibiotic treatment after incision and drainage. The purpose of this study is to compare successful rates of cure of abscesses less than 5 cm with antibiotic (oral TMP/SMX) versus non-antibiotic treatment after incision and drainage.
Detailed Description
This study is a randomized controlled trial of antibiotic treatment versus placebo after incision and drainage of skin and soft tissue abscesses less than 5 cm in pediatric patients. Eligible patients whose parents/guardians consented them to enrollment were randomized to receive one of two interventions: oral trimethoprim/sulfamethoxazole (TMP/SMX) or placebo after incision and drainage. Every attempt was made to make the placebo capsules and suspensions appear in all aspects like the true drug (was done by the investigational pharmacy department at our institution). Equal numbers of subjects were randomized at the outset to both study groups. Randomization, also done by our investigational pharmacy department, was done in blocks of 20. Patients were followed up in our emergency center at 24 to 48 hours to have any packing removed and to have their clinical/wound status assessed. They were not charged for this visit, and their valet parking was validated. If an individual patient, or an individual patient's wound, was felt to be not improving adequately, that patient was started on formal antibiotic therapy at the treating attending physician's discretion. Primary outcome: 1. Abscess resolution by parental report 7-10 days after incision and drainage Secondary outcomes: Admission to the hospital because of worsening infection Receipt of antibiotics (placebo arm) or change in antibiotics (antibiotic arm)

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Abscess
Keywords
abscess, Abscesses in the pediatric emergency population

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
oral trimethoprim/sulfamethoxazole
Arm Type
Active Comparator
Arm Description
subjects with abscesses less than 5cm will be randomized to either study med or placebo
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Placebo after incision and drainage of abscess less than 5 cm.
Intervention Type
Drug
Intervention Name(s)
oral trimethoprim/sulfamethoxazole
Other Intervention Name(s)
TMP/SMX
Intervention Description
80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo caps
Intervention Description
Placebo caps or suspension every 12 hours for 10 days
Primary Outcome Measure Information:
Title
Number of Participants With Abscess Resolution
Description
Outcomes will be measured by resolution of size, tenderness, and induration with erythema by parental report 7 - 10 days after initial visit to the Emergency Center
Time Frame
10 days
Secondary Outcome Measure Information:
Title
Number of Participants Requiring Admission for Failure of Abscess Resolution
Description
Percentage of patients requiring admission to Texas Children's or another hospital within 10 days of incision and drainage
Time Frame
10 days
Title
Number of Participants Requiring New or Modified Antibiotics for Failure of Abscess to Resolve
Description
For the antibiotic arm, we determined if the child was prescribed a different antibiotic. For the placebo arm, we determined if the child received a prescription for an antibiotic at a subsequent visit (e.g., in the emergency department, by their pediatrician, etc) within 10 days of incision and drainage
Time Frame
10 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
90 Days
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 1.) Abscess < 5 cm (< 5 cm of induration and fluctuance) requiring incision and drainage 2.) Age > 90 days and < 18 years 3.) Abscess on the trunk, scalp, extremities, or axillae Exclusion Criteria: Multiple abscesses Abscess located on the hands, face, or perineum Abscess as a result of a bite wound Immunocompromised patient - i.e., diabetes, sickle cell, chronic steroid therapy (> 10 days), etc. Previously failed 48 hours or greater therapy on any antibiotic regimen 6.) Drug allergy to TMP/SMX 7.) Fever > or = 102.2 degrees Fahrenheit in the previous 24 hours 8.) Systemic symptoms on presentation - i.e., nausea , vomiting, persistent tachycardia, hypotension, diaphoresis, etc. 9.) Signs /symptoms of another infection or illness - i.e., influenza, croup, etc.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Cruz, MD, MPH
Organizational Affiliation
Baylor College of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Texas Children's Hospital
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Management of Skin and Soft Tissue Abscesses in Pediatric Patients After Incision and Drainage

We'll reach out to this number within 24 hrs